SARS-CoV-2

The answer to stopping the coronavirus may be up the nose

The answer to stopping the coronavirus may be up the nose

The Covid-19 vaccines authorized for use today were developed at unprecedented speed and surpassed expectations in how well they worked. The billions of people who are protected by them have avoided severe symptoms, hospitalization and deaths. These vaccines are a scientific success beyond measure. And yet they could be even better. The enemy has evolved, …

The answer to stopping the coronavirus may be up the nose Read More »

Exploring age-associated differences in T lymphocyte immune responses after BNT162b2 vaccination

In a recent study posted to the bioRxiv* preprint server, researchers compared the immunogenicity of, and reactogenicity to, the BNT162b2 vaccine, a coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine, in Japanese adults and elders. Study: Delayed antigen-specific CD4+ T-cell induction correlates with impaired immune responses to SARS-COV-2 mRNA vaccination in the elderly. Image …

Exploring age-associated differences in T lymphocyte immune responses after BNT162b2 vaccination Read More »

CDC study of pregnant women hospitalized with COVID in 2021 found 93% not vaccinated

In a recent study posted to the Research Square* preprint server, researchers assessed the characteristics and treatment of coronavirus disease 2019 (COVID-19) in pregnant women. Various studies have reported that pregnant women are at a higher risk of severe disease outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Despite this, a significant number …

CDC study of pregnant women hospitalized with COVID in 2021 found 93% not vaccinated Read More »

Simulating molecular dynamics of SARS-CoV-2 spike variants in the locked conformation

In a recent study posted to the bioRxiv* pre-print server, researchers retrieved the first-ever sequenced spike (S) protein structures of the original Wuhan-Hu 1 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain, the Alpha, Delta, Delta-plus variants , and Omicron sub-variants BA.1 and BA.2 and compared their structural and molecular level variations. Study: Molecular dynamics …

Simulating molecular dynamics of SARS-CoV-2 spike variants in the locked conformation Read More »

Severe symptoms result in high titers of SARS-CoV-2 antibodies

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the novel coronavirus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drastically affected the global healthcare system and economy. SARS-CoV-2 causes asymptomatic to severe infection, which sometimes results in death. Scientists observed that active replication of the virus occurs in the early stage of the …

Severe symptoms result in high titers of SARS-CoV-2 antibodies Read More »

Third BNT162b2 dose elicits more durable immune response than second dose

In a recent study posted to the medRxiv* preprint server, researchers evaluated the durability of immune responses post-third dose of the BNT162b2 vaccine. Study: Durability of the immune response to a third BNT162b2 dose; five months follow-up. Image Credit: Telnov Oleksii/Shutterstock The coronavirus disease 2019 (COVID-19) pandemic has negatively affected human lives and remains an …

Third BNT162b2 dose elicits more durable immune response than second dose Read More »

Researchers investigate IgG antibodies against Mtb proteins in an Asian elephant cured of tuberculosis

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (mtb); the leading cause of human death due to a single pathogen before the emergence of SARS-CoV-2. In elephants, the infections and deaths with TB have been reported worldwide, and elephant-to-human transmission has also been reported. Therefore, elephant TB is a concern for both conservation …

Researchers investigate IgG antibodies against Mtb proteins in an Asian elephant cured of tuberculosis Read More »

Protection against SARS-CoV-2 highest after infection-acquired immunity boosted with vaccination in health care workers

1. SARS-CoV-2 infection-acquired immunity waned after 1 year, but immune protection remained high beyond 1 year in those boosted with vaccination. Evidence Rating Level: 2 (Good) Study Rundown: The effectiveness and duration of immune protection following SARS-CoV-2 vaccination or infection remains contested and relevant to ongoing vaccination strategies. In this prospective study named the SARS-CoV-2 …

Protection against SARS-CoV-2 highest after infection-acquired immunity boosted with vaccination in health care workers Read More »

The potential impact of oral vaccination against COVID-19 on transmission to naïve individuals studied in a hamster infection model

A recent article published in Science Translational Medicine demonstrated that mucosally delivered adenovirus type 5 (Ad5)-based coronavirus disease 2019 (COVID-19) vaccination minimized COVID-19 transmission and severity. Study: Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Image Credit: sdecoret/Shutterstock Background The currently approved intramuscular (IM) severe …

The potential impact of oral vaccination against COVID-19 on transmission to naïve individuals studied in a hamster infection model Read More »